Drug Trial Radar · NCT06105151
Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Oct 27, 2023
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Oct 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food Effect (FE) study
Conditions
- Schizophrenia
Interventions
VV119(SAD)Drug
VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;
VV119 Placebo(SAD)Drug
VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;
VV119(FE)Drug
A:2 mg VV119, following an overnight fast of at least 10 hours for Period 1; 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2; B: 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1;2mg VV119, following an overnight fast of at least 10 hours for Period 2;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: 23 days after treatment in part Ⅰ;
- Incidence of Treatment-Emergent Adverse EventsTime frame: 56 days after treatment in part Ⅱ;
- CmaxTime frame: 360 hours after dosing in part Ⅰ;
- CmaxTime frame: 480 hours after dosing in part Ⅱ;
- area under the plasma concentration time curve from time zero to the last(AUC0-t)Time frame: 360 hours after dosing in part Ⅰ;
- area under the plasma concentration time curve from time zero to the last(AUC0-t)Time frame: 480 hours after dosing in part Ⅱ;
- AUC0-∞Time frame: 360 hours after dosing in part Ⅰ;
- AUC0-∞Time frame: 480 hours after dosing in part Ⅱ;
- TmaxTime frame: 360 hours after dosing in part Ⅰ;
- TmaxTime frame: 480 hours after dosing in part Ⅱ;
- t1/2Time frame: 360 hours after dosing in part Ⅰ;
- t1/2Time frame: 480 hours after dosing in part Ⅱ;
- Apparent Clearance Rate(CL/F)Time frame: 360 hours after dosing in part Ⅰ;
- Apparent Clearance Rate(CL/F)Time frame: 480 hours after dosing in part Ⅱ;
- Vd/FTime frame: 360 hours after dosing in part Ⅰ;
- Vd/FTime frame: 480 hours after dosing in part Ⅱ;
- KeTime frame: 360 hours after dosing in part Ⅰ;
- KeTime frame: 480 hours after dosing in part Ⅱ;
- mean Resident Time from time zero to the last(MRT0-t)Time frame: 360 hours after dosing in part Ⅰ;
- mean Resident Time from time zero to the last(MRT0-t)Time frame: 480 hours after dosing in part Ⅱ;
- mean Resident Time from time zero to infinity(MRT0-∞)Time frame: 360 hours after dosing in part Ⅰ;
- mean Resident Time from time zero to infinity(MRT0-∞)Time frame: 480 hours after dosing in part Ⅱ;
- AUC_%ExtraTime frame: 360 hours after dosing in part Ⅰ;
- AUC_%ExtraTime frame: 480 hours after dosing in part Ⅱ;
- BPTime frame: 360 hours after dosing in part Ⅰ;
- BPTime frame: 480 hours after dosing in part Ⅱ;
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anding Hospital of Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.